Baseline characteristics and preliminary outcomes stratified by CYP3A genotypes

	CYP3A4 A–392G (n = 135)				CYP3A4 T16090C (n = 145)				CYP3A5 A6986G (n = 146)
	A/A (n = 10)	A/G (n = 70)	G/G (n = 55)	p	C/C (n = 13)	T/C (n = 79)	T/T (n = 53)	p	A/A (n = 74)	A/G (n = 64)	G/G (n = 8)	p
Number randomized to low MAP (%)	4 (40)	31 (44)	32 (58)		7 (53)	40 (49)	28 (53)		39 (52)	31 (47)	5 (63)
Number of men (%)	6 (60)	48 (69)	20 (37)		8 (61)	45 (55)	29 (55)		33 (44)	41 (62)	8 (100)
Number who did not reach target (%)	0	9 (13)	2 (4)	0.26	1 (8)	3 (4)	4 (8)	0.66	1 (1)	6 (9)	1 (12)	0.07
Age, years	53 ± 10	53 ± 11	52 ± 11	0.96	53 ± 12	52 ± 11	53 ± 10	0.90	53 ± 11	53 ± 11	49 ± 13	0.74
Baseline MAP, mm Hg	106 ± 21	114 ± 19	115 ± 15	0.38	117 ± 22	115 ± 17	114 ± 18	0.69	114 ± 16	115 ± 20	120 ± 18	0.58
Body mass index, kg/m2	31 ± 7	30 ± 7	32 ± 6	0.52	29 ± 7	31 ± 7	31 ± 6	0.36	31 ± 7	30 ± 6	30 ± 5	0.30
Serum creatinine, mg/dl	2.24 ± 0.82	2.21 ± 0.90	1.88 ± 0.72	0.07	2.03 ± 1.0	2.01 ± 0.74	2.11 ± 0.88	0.56	1.99 ± 0.78	2.01 ± 0.83	2.8 ± 0.66	0.09
Glomerular filtration rate ml/min per 1.73 m2	42 ± 15	45 ± 13	47 ± 12	0.39	46 ± 12	47 ± 13	45 ± 12	0.54	46 ± 12	47 ± 13	39 ± 14	0.55
Total cholesterol, mg/dl	227 ± 54	207 ± 50	219 ± 46	0.26	202 ± 29	212 ± 50	218 ± 48	0.28	216 ± 47	211 ± 47	216 ± 57	0.69
Average number of daily medications	2.89 ± 1.17	3.76 ± 1.34	3.41 ± 1.12	0.07	3.3 ± 1.1	3.5 ± 1.3	3.6 ± 1.3	0.36	3.5 ± 1.2	3.6 ± 1.3	3.3 ± 1.4	0.78
Average MAP in first year after randomization	99 ± 6	101 ± 7	100 ± 6	0.55	101 ± 10	100 ± 6	100 ± 7	0.94	100 ± 6	101 ± 7	98 ± 9	0.94